Research ExplorerPublicationsSecond allogeneic haematopoietic cell transplantation using ...

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia

Standard

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. / Kharfan-Dabaja, Mohamed A; Labopin, Myriam; Brissot, Eolia; Kroger, Nicolaus; Finke, Jürgen; Ciceri, Fabio; Deconinck, Eric; Blaise, Didier; Chevallier, Patrice; Gramatzki, Martin; Ganser, Arnold; Stelljes, Matthias; Edinger, Matthias; Savani, Bipin; Ruggeri, Annalisa; Sanz, Jaime; Nagler, Arnon; Mohty, Mohamad.

In: BRIT J HAEMATOL, Vol. 193, No. 3, 05.2021, p. 592-601.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kharfan-Dabaja, MA, Labopin, M, Brissot, E, Kroger, N, Finke, J, Ciceri, F, Deconinck, E, Blaise, D, Chevallier, P, Gramatzki, M, Ganser, A, Stelljes, M, Edinger, M, Savani, B, Ruggeri, A, Sanz, J, Nagler, A & Mohty, M 2021, 'Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia', BRIT J HAEMATOL, vol. 193, no. 3, pp. 592-601. https://doi.org/10.1111/bjh.17426

APA

Kharfan-Dabaja, M. A., Labopin, M., Brissot, E., Kroger, N., Finke, J., Ciceri, F., Deconinck, E., Blaise, D., Chevallier, P., Gramatzki, M., Ganser, A., Stelljes, M., Edinger, M., Savani, B., Ruggeri, A., Sanz, J., Nagler, A., & Mohty, M. (2021). Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. BRIT J HAEMATOL, 193(3), 592-601. https://doi.org/10.1111/bjh.17426

Vancouver

Kharfan-Dabaja MA, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. BRIT J HAEMATOL. 2021 May;193(3):592-601. https://doi.org/10.1111/bjh.17426

Bibtex

@article{8f7b748855474a65b5d0d5f808b5b816,
title = "Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia",
abstract = "Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo-HCT from a human leucocyte antigen (HLA)-matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged ≥18 years who received a second allo-HCT for treating AML relapse between 2005 and 2019. The primary end-point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35-58) versus haploidentical 44 (33-53) years (P = 0·07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0·57). Similarly, the 2-year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1·42, 95% confidence interval (CI) 1·07-1·89; P = 0·02]. Conversely, a longer time from first allo-HCT to relapse (>13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37-0·69; P < 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission.",
keywords = "Adult, Allografts, Disease-Free Survival, Female, HLA Antigens, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Leukemia, Myeloid, Acute/mortality, Lymphocyte Depletion, Male, Middle Aged, Retrospective Studies, Survival Rate, T-Lymphocytes, Unrelated Donors",
author = "Kharfan-Dabaja, {Mohamed A} and Myriam Labopin and Eolia Brissot and Nicolaus Kroger and J{\"u}rgen Finke and Fabio Ciceri and Eric Deconinck and Didier Blaise and Patrice Chevallier and Martin Gramatzki and Arnold Ganser and Matthias Stelljes and Matthias Edinger and Bipin Savani and Annalisa Ruggeri and Jaime Sanz and Arnon Nagler and Mohamad Mohty",
note = "{\textcopyright} 2021 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2021",
month = may,
doi = "10.1111/bjh.17426",
language = "English",
volume = "193",
pages = "592--601",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia

AU - Kharfan-Dabaja, Mohamed A

AU - Labopin, Myriam

AU - Brissot, Eolia

AU - Kroger, Nicolaus

AU - Finke, Jürgen

AU - Ciceri, Fabio

AU - Deconinck, Eric

AU - Blaise, Didier

AU - Chevallier, Patrice

AU - Gramatzki, Martin

AU - Ganser, Arnold

AU - Stelljes, Matthias

AU - Edinger, Matthias

AU - Savani, Bipin

AU - Ruggeri, Annalisa

AU - Sanz, Jaime

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - © 2021 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2021/5

Y1 - 2021/5

N2 - Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo-HCT from a human leucocyte antigen (HLA)-matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged ≥18 years who received a second allo-HCT for treating AML relapse between 2005 and 2019. The primary end-point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35-58) versus haploidentical 44 (33-53) years (P = 0·07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0·57). Similarly, the 2-year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1·42, 95% confidence interval (CI) 1·07-1·89; P = 0·02]. Conversely, a longer time from first allo-HCT to relapse (>13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37-0·69; P < 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission.

AB - Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo-HCT from a human leucocyte antigen (HLA)-matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged ≥18 years who received a second allo-HCT for treating AML relapse between 2005 and 2019. The primary end-point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35-58) versus haploidentical 44 (33-53) years (P = 0·07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0·57). Similarly, the 2-year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1·42, 95% confidence interval (CI) 1·07-1·89; P = 0·02]. Conversely, a longer time from first allo-HCT to relapse (>13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37-0·69; P < 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission.

KW - Adult

KW - Allografts

KW - Disease-Free Survival

KW - Female

KW - HLA Antigens

KW - Hematopoietic Stem Cell Transplantation

KW - Histocompatibility Testing

KW - Humans

KW - Leukemia, Myeloid, Acute/mortality

KW - Lymphocyte Depletion

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Survival Rate

KW - T-Lymphocytes

KW - Unrelated Donors

U2 - 10.1111/bjh.17426

DO - 10.1111/bjh.17426

M3 - SCORING: Journal article

C2 - 33838047

VL - 193

SP - 592

EP - 601

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

ER -